Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A dual timeline of safinamide effects in Parkinson's disease: mechanistic rationale and clinical implications.

Frontiers in neurology·2026
Same author

Disease modification in advanced Parkinson's disease: a review and roadmap for paving the way for next-generation interventions.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Biochemical and nutritional changes during continuous subcutaneous apomorphine infusion in advanced Parkinson's disease: findings from an observational cohort.

Therapeutic advances in neurological disorders·2026
Same author

National implementation of a digital Parkinson's disease screening programme in Thailand: reach, adoption, and real-world performance of the CheckPD app.

BMC public health·2026
Same author

The taste of Parkinson's: How food choices reflect nutritional health.

Journal of Parkinson's disease·2026
Same author

Revisiting the 2015 MDS diagnostic criteria for Parkinson disease: insights from autopsy-confirmed cases.

NPJ Parkinson's disease·2025
Same journal

Artificial Intelligence in the Prehospital Stage of Stroke: Can Virtual Assistants Optimize Triage?

The neurologist·2026
Same journal

Looking Beyond the Midline: An Uncommon Etiology of Internuclear Ophthalmoplegia of Abduction Due to Cerebral Venous Thrombosis.

The neurologist·2026
Same journal

Commentary: Cervical Artery Dissection and Chiropractic Cervical Manipulation: Clarifying Association, Mechanism, and Interpretation.

The neurologist·2026
Same journal

Acute Spinal Cord Infarct Secondary to Fibrocartilaginous Embolism Treated With Tenecteplase.

The neurologist·2026
Same journal

Cervical Artery Dissection and Chiropractic​​​​​.

The neurologist·2026
Same journal

Oromandibular Dyskinesia Associated With Levofloxacin and Responsive to Low-Dose Oral Diazepam: A Case Report.

The neurologist·2026
See all related articles

Related Experiment Video

Updated: Jul 3, 2026

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

Multiple system atrophy.

Roongroj Bhidayasiri1, Helen Ling

  • 1Division of Neurology, Chulalongkorn Comprehensive Movement Disorders Center, Chulalongkorn Univerisity Hospital, Bangkok, Thailand. rbh1@ucla.edu

The Neurologist
|July 12, 2008
PubMed
Summary
This summary is machine-generated.

Multiple system atrophy (MSA) is a complex neurodegenerative disease. While no cure exists, symptomatic treatments can help manage motor and non-motor symptoms, improving patient quality of life.

More Related Videos

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Related Experiment Videos

Last Updated: Jul 3, 2026

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Area of Science:

  • Neuroscience
  • Neurology

Background:

  • Multiple system atrophy (MSA) is a rare neurodegenerative disorder characterized by autonomic dysfunction, parkinsonism, and cerebellar symptoms.
  • Despite nearly four decades since its initial description, differentiating MSA from its mimics and providing effective treatments remain significant clinical challenges.

Purpose of the Study:

  • To review current knowledge and advances in understanding multiple system atrophy (MSA).
  • To highlight key clinical features for accurate diagnosis of MSA.
  • To outline available therapeutic strategies for managing MSA.

Main Methods:

  • This study is a comprehensive review of existing literature on multiple system atrophy (MSA).
  • Analysis of clinical presentations and diagnostic markers.
  • Evaluation of current and emerging treatment options.

Main Results:

  • Advances in understanding MSA pathophysiology and clinical features have been made.
  • Distinct pathologic markers aid in recognizing MSA as a unique disease entity.
  • Symptomatic treatments can offer transient relief for both motor and non-motor symptoms.

Conclusions:

  • Currently, no treatment can halt the progression of multiple system atrophy (MSA).
  • Symptomatic treatments are crucial for ameliorating non-motor and motor features of MSA.
  • Available therapies should be utilized to improve the quality of life for patients with MSA.